Search
Zimelidine
go.drugbank.com/drugs/DB04832ApprovedWithdrawnZimelidine has been banned worldwide due to serious, sometimes fatal, cases of central and/or peripheral neuropathy known as Guillain-Barré syndrome and due to a peculiar hypersensitivity reaction involving
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesCyclandelate
go.drugbank.com/drugs/DB04838ApprovedWithdrawnA direct-acting smooth muscle relaxant used to dilate blood vessels. It may cause gastrointestinal distress and tachycardia.
Roxadustat
go.drugbank.com/drugs/DB04847ApprovedInvestigationalRoxadustat is a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor used to treat anemia associated with chronic kidney disease. … It works by reducing the breakdown of the hypoxia-inducible factor (HIF), which is a transcription factor that stimulates red blood cell production in response to low oxygen levels.
Zanapezil
go.drugbank.com/drugs/DB04859ExperimentalZanapezil (TAK-147) is a selective acetylcholine (ACh) esterase inhibitor under investigation as a drug for Alzheimer's disease (AD) treatment.
Merimepodib
go.drugbank.com/drugs/DB04862InvestigationalMerimepodib (VX-497) is a novel noncompetitive inhibitor of IMPDH.
Huperzine A
go.drugbank.com/drugs/DB04864ApprovedInvestigationalWithdrawnHuperzine A, is a naturally occurring sesquiterpene alkaloid found in the extracts of the firmoss _Huperzia serrata_. … It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.
Synonyms: L-huperzine A, Huperzine ACategories: Compounds used in a research, industrial, or household settingHalofuginone
go.drugbank.com/drugs/DB04866InvestigationalVet approvedHalofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression.
Olcegepant
go.drugbank.com/drugs/DB04869InvestigationalBoehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks … Olcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine.